cross-posted from: https://lemmy.world/post/9298788

The Biden Administration on Thursday announced it is setting new policy that will allow it to seize patents for medicines developed with government funding if it believes their prices are too high.

The policy creates a roadmap for the government’s so-called march-in rights, which have never been used before. They would allow the government to grant additional licenses to third parties for products developed using federal funds if the original patent holder does not make them available to the public on reasonable terms.

Under the draft roadmap, seen by Reuters, the government will consider factors including whether only a narrow set of patients can afford the drug, and whether drugmakers are exploiting a health or safety issue by hiking prices.

“We’ll make it clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House adviser Lael Brainard said on a press call.

  • BossDj@lemm.ee
    link
    fedilink
    arrow-up
    5
    ·
    1 year ago

    Leaving it vague allows the government more leeway, and companies less opportunities for “well, technically” gotchas from their scores of lawyers

    • Surely youre right, because the answer of whether they are too high is ‘yes’ for every drug sold in the us.

      I guess I’m interested in how they are using it, if at all. If Biden plans on reducing 'scrips in time for the election it could help pump his numbers up i guess? I’m just spitballing, cuz i can’t see how it’s gonna be used. i am too cynical after all these years to believe the poor get any breaks.

      • BossDj@lemm.ee
        link
        fedilink
        arrow-up
        4
        ·
        1 year ago

        Of you want to be cynical, I’ll bet it’s only used on companies with whom the administration makes behind the scenes deals with before going public with it. Financial or helping them look good, or offering future contracts